Astellas Pharma Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Net Income	383,949	31,237	24,969	132,361	156,886	145,324
Depreciation & Amortization	191,917	199,132	157,840	105,738	79,684	72,652
Loss (Gain) From Sale of Assets	210,238	187,564	78,931	84,499	74,850	100,348
Other Operating Activities	-67,390	-75,674	-37,563	-68,811	-43,293	-27,144
Change in Accounts Receivable	-106,940	-104,735	-55,948	-4,849	-8,001	22,161
Change in Inventory	-29,441	-50,225	-60,036	-7,086	24,058	-2,318
Change in Accounts Payable	-13,877	-11,409	29,466	-12,274	-10,101	-51,569
Change in Other Net Operating Assets	70,498	18,622	34,816	98,189	-16,639	47,389
Operating Cash Flow	457,846	194,512	172,475	327,767	257,444	306,843
Operating Cash Flow Growth	176.78%	12.78%	-47.38%	27.32%	-16.10%	38.22%
Capital Expenditures	-50,820	-37,003	-38,056	-36,441	-30,739	-31,384
Sale of Property, Plant & Equipment	-	-	-	-	441	6,831
Cash Acquisitions	-	-	-784,974	-	-670	-14,916
Sale (Purchase) of Intangibles	-26,764	-19,168	-33,438	-51,888	-21,428	-46,057
Investment in Securities	12,920	12,920	-	12,624	-	-
Other Investing Activities	15,719	-46,168	10,666	-8,795	-10,017	3,632
Investing Cash Flow	-48,945	-89,419	-845,802	-84,500	-62,413	-81,894
Short-Term Debt Issued	-	-	324,337	-	-	-
Long-Term Debt Issued	-	200,000	472,275	50,000	-	80,000
Total Debt Issued	-	200,000	796,612	50,000	-	80,000
Short-Term Debt Repaid	-	-236,449	-	-15,000	-	-
Long-Term Debt Repaid	-	-52,073	-25,379	-50,000	-60,000	-206,000
Total Debt Repaid	-179,038	-288,522	-25,379	-65,000	-60,000	-206,000
Net Debt Issued (Repaid)	-179,038	-88,522	771,233	-15,000	-60,000	-126,000
Repurchase of Common Stock	-731	-6,960	-10,735	-60,556	-50,717	-9,163
Common Dividends Paid	-136,099	-128,993	-116,653	-100,355	-85,236	-76,157
Other Financing Activities	-21,577	-36,892	-29,785	-19,712	-20,345	-18,159
Financing Cash Flow	-337,445	-261,367	614,060	-195,623	-216,298	-229,479
Foreign Exchange Rate Adjustments	2,975	8,960	18,113	13,210	11,125	12,267
Miscellaneous Cash Flow Adjustments	-1	-1	1	-	-1	-
Net Cash Flow	74,430	-147,315	-41,153	60,854	-10,143	7,737
Free Cash Flow	407,026	157,509	134,419	291,326	226,705	275,459
Free Cash Flow Growth	219.03%	17.18%	-53.86%	28.50%	-17.70%	52.41%
Free Cash Flow Margin	19.75%	8.24%	8.38%	19.18%	17.49%	22.05%
Free Cash Flow Per Share	225.84	87.64	74.69	159.63	122.50	148.24
Cash Income Tax Paid	89,759	85,478	38,112	69,479	42,093	17,870
Levered Free Cash Flow	301,369	125,260	134,671	202,242	174,913	155,051
Unlevered Free Cash Flow	308,381	133,980	139,311	204,253	176,360	156,375
Change in Working Capital	-79,760	-147,747	-51,702	73,980	-10,683	15,663

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.